TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aziyo Biologics ( (ELUT) ) has provided an announcement.
On September 8, 2025, Elutia Inc. entered into an agreement to sell its cardiac implantable electronic device business to Boston Scientific Corporation for $88 million. This transaction is expected to close in the fourth quarter of 2025 and will allow Elutia to focus on its drug-eluting biomatrix solutions in breast reconstruction, strengthen its financial position, and eliminate outstanding debt. The sale marks a strategic shift for Elutia, enabling it to advance its SimpliDerm franchise and drug-eluting pipeline without shareholder dilution, thereby enhancing long-term shareholder value.
The most recent analyst rating on (ELUT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.
Spark’s Take on ELUT Stock
According to Spark, TipRanks’ AI Analyst, ELUT is a Neutral.
Aziyo Biologics’ overall stock score is primarily impacted by its poor financial performance, with significant losses and negative equity. While the earnings call provided some positive insights into product growth and strategic initiatives, the technical analysis and valuation remain weak, contributing to a low overall score.
To see Spark’s full report on ELUT stock, click here.
More about Aziyo Biologics
Elutia Inc. is a company specializing in the development and commercialization of drug-eluting biomatrix products aimed at improving compatibility between medical devices and patients. The company focuses on leveraging its proprietary technology platform to address unmet clinical needs, particularly in the breast reconstruction market.
Average Trading Volume: 34,263
Technical Sentiment Signal: Sell
Current Market Cap: $79.7M
See more insights into ELUT stock on TipRanks’ Stock Analysis page.